MDX-124 inhibits 4T1-luc triple-negative breast tumor growth in vivo. BALB/c mice (n = 12 per group) were inoculated orthotopically with 4T1-luc murine triple-negative breast cancer cells (5 × 10^4) and randomized to receive either MDX-124 (1 mg/kg) or a vehicle control (PBS) treatment via intravenous injection on day 1 and day 8. A Tumor volume and B body weight measured at each corresponding time point. Arrows indicate day of dosing treatments received. Data are presented as the mean ± SEM with statistical significance calculated via mixed-effects model (REML) and indicated by ****p